.jpeg)
2026-09-28 04:52:25
Belumosudil is a ROCK2 inhibitor for chronic graft-versus-host disease in patients aged 12 years and older after inadequate response to prior systemic therapy. Use 200mg once daily with food; manage embryo-fetal risk and contraception, strong CYP3A inducers/PPI dosing changes, monthly liver tests, and infection or hypertension adverse events.
2026-09-14 03:29:24
Acalabrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma is assessed by age, stage, TP53/17p status, prior therapy, and relapse. Long-term data support progression-free survival and durable disease control rather than a fixed “added years” estimate.
2026-09-14 03:25:01
Bosutinib is used for Ph+ chronic myeloid leukemia. Symptom change in a few days does not reflect efficacy. Response is tracked by CBC, BCR-ABL quantification, and cytogenetics; molecular remission often takes months, with mutation retesting for T315I/V299L.
2026-09-14 03:16:19
Acalabrutinib is usually 100mg twice daily for CLL/SLL monotherapy or with obinutuzumab, and for transplant-ineligible newly diagnosed MCL with bendamustine plus rituximab. This guide simplifies dosing, toxicity breaks, and interactions.
2026-09-14 03:06:37
Bosutinib is a BCR-ABL and Src-family tyrosine kinase inhibitor for newly diagnosed and resistant/intolerant Philadelphia chromosome-positive chronic myeloid leukemia, covering chronic, accelerated, blast phases and pediatric chronic-phase use.
2026-09-10 02:52:45
A multicenter Ib/II trial shows the azacitidine + venetoclax + ivosidenib triplet regimen achieves 95% ORR in newly diagnosed IDH1-mutant AML with manageable safety.
2026-09-07 05:13:58
Does anagrelide worsen myelofibrosis in essential thrombocythemia (ET)? This article reviews clinical evidence, distinguishes drug effects from natural disease progression, and highlights monitoring strategies.
2026-09-03 05:11:16
Learn about Acalabrutinib (Calquence) recommended dosage (100mg twice daily), continuous treatment approach for CLL, MCL and SLL, administration tips, and adverse reaction management.
2026-09-01 04:25:06
Enasidenib is an oral small-molecule inhibitor of mutant IDH2. By lowering the oncometabolite 2-hydroxyglutarate (2-HG) and promoting myeloid differentiation, it is used in relapsed or refractory AML with an IDH2 mutation.
2026-09-01 03:18:35
Five-year OPTIC data show that response-based ponatinib dosing — starting at 45 mg and reducing to 15 mg after response — delivers durable molecular responses and long-term survival in third-line chronic-phase CML, with a markedly improved safety profile.
2026-08-31 03:30:32
Midostaurin is an oral multi-kinase inhibitor approved for FLT3 mutation–positive newly diagnosed AML and for ASM, SM-AHN and MCL — with distinctly different dosing for each indication.
2026-08-26 07:14:21
Bosutinib is a BCR-ABL/SRC tyrosine kinase inhibitor primarily indicated for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This article reviews its established indications, investigational use in autosomal dominant polycystic kidney disease (ADPKD), and critical safety boundaries.
